Skip to main content

Research Repository

Advanced Search

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

People Involved

Professor Andrew Clark A.L.Clark@hull.ac.uk

Project Description

Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study drug which facilitates heart muscle contraction via interaction with the actin - myosin complex, versus placebo.

Type of Project Project
Project Acronym Galactic-HF
Status Project Live
Funder(s) AMGEN Limited
Value £110,723.00
Project Dates Apr 1, 2017 - Jul 31, 2021

You might also like

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Dec 31, 2019
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More